Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection

2014; Oxford University Press; Volume: 69; Issue: 11 Linguagem: Inglês

10.1093/jac/dku257

ISSN

1460-2091

Autores

Dilip Nathwani, Oliver A. Cornely, A. K. van Engen, O. Odufowora-Sita, P. Retsa, Isaac Odeyemi,

Tópico(s)

Helicobacter pylori-related gastroenterology studies

Resumo

ObjectivesFidaxomicin was non-inferior to vancomycin with respect to clinical cure rates in the treatment of Clostridium difficile infections (CDIs) in two Phase III trials, but was associated with significantly fewer recurrences than vancomycin. This economic analysis investigated the cost-effectiveness of fidaxomicin compared with vancomycin in patients with severe CDI and in patients with their first CDI recurrence.

Referência(s)